APA

Swords R. T., Watts J., Erba H. P., Altman J. K., Maris M., Anwer F., Hua Z., Stein H., Faessel H., Sedarati F., Dezube B. J., Giles F. J., Medeiros B. C. & DeAngelo D. J. (20180827). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. : Blood cancer journal.

Chicago

Swords R T, Watts J, Erba H P, Altman J K, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube B J, Giles F J, Medeiros B C and DeAngelo D J. 20180827. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. : Blood cancer journal.

Harvard

Swords R. T., Watts J., Erba H. P., Altman J. K., Maris M., Anwer F., Hua Z., Stein H., Faessel H., Sedarati F., Dezube B. J., Giles F. J., Medeiros B. C. and DeAngelo D. J. (20180827). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. : Blood cancer journal.

MLA

Swords R T, Watts J, Erba H P, Altman J K, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube B J, Giles F J, Medeiros B C and DeAngelo D J. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. : Blood cancer journal. 20180827.